Stacy Lindborg

And in fact, we know that both healthy cells and cancer cells alike uptake the product and then start producing IL-12, interferon gamma, TGF alpha, this powerful change to the microtumor environment.

It's an amazing

process, that's the goal of the therapy.

We can actually measure through ascites, which is the fluid in the peritoneal cavity.

We can take it out and we can actually see these many fold increases that the product is doing what we want.

We see downstream effects.

And then when we get to clinical data, we can see that women, the median is substantially improved.

So we're seeing really what the holy grail is with ovarian cancer that we're able to, for the first time,

extend overall survival.

A combination chemotherapy is the current standard of care.

So more women are getting it before surgery.

That used to be some were treated before surgery, some were treated surgery and then, and then chemo.

Really what we're seeing now is that if women can tolerate and can accept it, almost everybody is starting to not move to neoadjuvant chemo, which allows the tumors to shrink.

then you can surgically remove more.

So you're getting more of the cancer and then they continue with chemotherapy.

So that's the standard of care.

If we think about, I'll just start with immunotherapies because that's what our product is.

So really the payload and what we're really triggering the immune system to start producing is IL-12.

It's a very important cytokine.

There have been